GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2025
0mins
Source: Businesswire
Financial Update: GenSight Biologics reported a cash position of €2.5 million as of December 31, 2024, down from €3.4 million in September 2024, and is working on optimizing cash management while awaiting regulatory clearance for its early access program.
Regulatory Progress: The French medicines safety agency ANSM is reviewing the quality dossier for LUMEVOQ®, with preparations ongoing for a new Phase III trial and submission to the UK’s MHRA, while the company anticipates needing additional financing to meet future obligations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
